Cardiovascular protective properties of kiwifruit extracts in vitro.
It is currently accepted that the consumption of fruit-derived antioxidants such as vitamin C, carotenoids, and flavonoids provides a preventive effect against cardiovascular disease. The purpose of the present study was to investigate potential cardiovascular protective properties of aqueous and 70% ethanol extracts from kiwifruit by analyzing the antioxidative, antihypertensive, hypocholesterolemic, and fibrinolytic activities in vitro. Aqueous and 70% ethanol extracts at 50 mg/ml showed DPPH-radical scavenging activities of 72.31% and 70.75%, respectively. Total antioxidant activity in linoleic acid emulsion was 85-88% at 10 mg/ml and 96-98% at 50 mg/ml of kiwifruit extract. Inhibitory activities against angiogensin I-converting enzyme of kiwifruit extracts were 21-26% at 10 mg/ml and 46-49% at 50 mg/ml, and inhibitory activities on HMG-CoA reductase were 13-14% at 10 mg/ml and 19-30% at 50 mg/ml. Fibrinolytic activity of kiwifruit was also observed at a high concentration of 100 mg/ml in both aqueous and 70% EtOH extracts. Based on our results, kiwifruit have potential cardiovascular protective properties in vitro.
Jung
Kyung-Ah
KA
Food Processing Technology, Korea Food Research Institute, Kyonggi-do, Republic of Korea.
Song
Tae-Chul
TC
Han
Daeseok
D
Kim
In-Ho
IH
Kim
Young-Eon
YE
Lee
Chang-Ho
CH
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D005341:Fibrinolysin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005638:Fruit / Q000737:chemistry*; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D066298:In Vitro Techniques; D019787:Linoleic Acid / Q000494:pharmacology; D008297:Male; D010851:Picrates; D010936:Plant Extracts / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000806:Angiotensin-Converting Enzyme Inhibitors; D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D000975:Antioxidants; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; D006834:Hydrazines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010851:Picrates; D010936:Plant Extracts; D019787:Linoleic Acid; C004931:1,1-diphenyl-2-picrylhydrazyl; D005341:Fibrinolysin